(ENTA)—EPVantage, which is normally a trustworthy provider of educated biotech opinion, is hedging like a sell-side analyst wrt ABBV's $3.5B HCV guidance:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.